Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Nuvation Bio Inc (NYSE: NUVB) closed at $8.96 in the last session, up 0.22% from day before closing price of $8.94. In other words, the price has increased by $0.22 from its previous closing price. On the day, 3.77 million shares were traded. NUVB stock price reached its highest trading level at $9.12 during the session, while it also had its lowest trading level at $8.87.
Ratios:
We take a closer look at NUVB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.39 and its Current Ratio is at 8.48. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.60.
On November 19, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $12.
On September 30, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $10.Jefferies initiated its Buy rating on September 30, 2025, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Liu Dongfang sold 150,000 shares for $7.82 per share. The transaction valued at 1,173,255 led to the insider holds 18,000 shares of the business.
DONGFANG LIU bought 150,000 shares of NUVB for $1,173,255 on Dec 01 ’25. On Nov 26 ’25, another insider, Liu Dongfang, who serves as the CHIEF MEDICAL OFFICER of the company, sold 10,000 shares for $8.00 each. As a result, the insider received 80,000 and left with 18,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NUVB now has a Market Capitalization of 3071787520 and an Enterprise Value of 2580290560. For the stock, the TTM Price-to-Sale (P/S) ratio is 115.17 while its Price-to-Book (P/B) ratio in mrq is 9.42. Its current Enterprise Value per Revenue stands at 96.467 whereas that against EBITDA is -11.144.
Stock Price History:
The Beta on a monthly basis for NUVB is 1.56, which has changed by 2.100346 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, NUVB has reached a high of $9.75, while it has fallen to a 52-week low of $1.54. The 50-Day Moving Average of the stock is 29.88%, while the 200-Day Moving Average is calculated to be 149.24%.
Shares Statistics:
According to the various share statistics, NUVB traded on average about 8.42M shares per day over the past 3-months and 5599240 shares per day over the past 10 days. A total of 341.76M shares are outstanding, with a floating share count of 239.39M. Insiders hold about 30.38% of the company’s shares, while institutions hold 53.82% stake in the company. Shares short for NUVB as of 1765756800 were 45976518 with a Short Ratio of 5.46, compared to 1763078400 on 66349138. Therefore, it implies a Short% of Shares Outstanding of 45976518 and a Short% of Float of 21.85.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.12 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.45 and -$0.45 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.28, with 1.0 analysts recommending between -$0.28 and -$0.28.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $32.58M. It ranges from a high estimate of $49.8M to a low estimate of $16.21M. As of. The current estimate, Nuvation Bio Inc’s year-ago sales were $5.71MFor the next quarter, 8 analysts are estimating revenue of $30.8M. There is a high estimate of $36.7M for the next quarter, whereas the lowest estimate is $22.3M.
A total of 9 analysts have provided revenue estimates for NUVB’s current fiscal year. The highest revenue estimate was $70.8M, while the lowest revenue estimate was $37.25M, resulting in an average revenue estimate of $54.54M. In the same quarter a year ago, actual revenue was $7.87MBased on 9 analysts’ estimates, the company’s revenue will be $173.75M in the next fiscal year. The high estimate is $207.7M and the low estimate is $126.2M.
